Trainer Todd Pletcher has been suspended 10 days by the New York stewards due to a positive test for meloxicam, a regulated anti-inflammatory drug, in the post-race sample of Forte after the horse won the Sept. 5 Hopeful Stakes last year at Saratoga Racecourse, the trainer and his legal representatives said. The penalty was communicated by Pletcher and his legal team to Daily Racing Form and other industry trade outlets on Thursday afternoon, in advance of the expected release of an official stewards ruling in the case later today. Pletcher and his attorney, Karen Murphy, said they would appeal the penalty, which also included the disqualification of Forte from the Hopeful and a $1,000 fine. Pletcher said that Forte was never prescribed or administered meloxicam, a non-steroidal anti-inflammatory drug that is a common ingredient in human pain relievers, and that he believed that the positive was the result of accidental contamination. The presence of meloxicam was confirmed in a split sample tested at Pletcher’s request and expense. “This horse came into our care March 25, 2022, and he was never prescribed or administered meloxicam ever under our care,” Pletcher said. For now, Pletcher said that Forte would be shipped back to his base at Belmont Park in New York, where he may target the third leg of the Triple Crown, the June 10 Belmont Stakes. The ruling is the latest development involving Forte, last year’s 2-year-old champion, over an extraordinarily eventful seven-day period. Last Saturday morning, Forte was scratched from the Kentucky Derby by the state veterinarian, two days after bobbling during a videotaped workout. On Tuesday night, three days after the scratch, the New York Times was the first to report that the horse had a pending medication violation in New York from last year that had yet to be adjudicated, creating widespread confusion and criticism among racing fans, the general public, and the mainstream media. The case has drawn widespread attention due to the eight-month gap between the horse’s positive test and the initial stewards’ hearing yesterday to address the positive. In between the positive test and the hearing, Forte made four starts, winning them all, and was voted the Eclipse Award winner as champion 2-year-old male. He was the morning-line favorite for the Derby at the time he was scratched. Pletcher said on Thursday that he was informed of the positive test on Sept. 28, on a day when Forte was expected to be entered for the Oct. 1 Champagne Stakes. When he was notified of the positive test, he was told that Forte would have to test clean for the drug before he could be entered. Since a test could not come back prior to entries being taken, Pletcher re-routed the horse to the Grade 1 Breeders’ Futurity at Keeneland Racecourse in Lexington on Oct. 8. Forte won the Futurity by neck. :: Bet the races on DRF Bets! Sign up with code WINNING to get a $250 Deposit Match, $10 Free Bet, and FREE DRF Formulator.  Pletcher’s legal team made Dr. Steven Barker, a former director of a testing lab in Louisiana, available for questions during a Thursday afternoon conference call with a select number of reporters. Barker, who frequently appears as an expert witness for trainers in regulatory hearings or court cases, said that the amount found in the samples could not have produced an effect in Forte in the Hopeful. “The level of medication gave him no advantage,” Barker said. “It didn’t endanger the horse. It didn’t endanger anyone else in the race. It didn’t do anything. It just happened to be there.” Meloxicam is a regulated medication, meaning that is permitted to be administered to horses for therapeutic purposes provided it does not appear in post-race samples. It is not as commonly used in racing as other NSAIDs, such as phenylbutazone or flunixin, and it is not one of three NSAIDs that have been approved for equine care. For penalty purposes, it is a Class B drug in the classification schemes of both the Association of Racing Commissioners International, which recommends penalties to state racing commissions, and the Horseracing Integrity and Safety Authority, which is scheduled to take over the administration of a national drug-testing and enforcement program later this month. The ARCI recommends a minimum suspension of 15 days "absent mitigating circumstances” for a meloxicam positive. HISA recommendations also call for a 15-day suspension, and the authority’s rules call for adjudicators to consider “mitigating” and “aggravating circumstances” in consideration of all penalties. Both call for disqualification of the horse from the race. The New York State Gaming Commission has not issued a penalty for a meloxicam positive in a Thoroughbred horse since 2013, according to its database. In that case, Dennis Lalman, an owner-trainer, was suspended for 15 days, but the penalty was reduced to seven days after he waived his right to appeal. Lalman’s horse was disqualified. Pletcher also confirmed on Friday that his horse Mind Control tested positive for an unidentified medication following the Sept. 24 Parx Dirt Mile at Parx racetrack outside of Philadelphia. In that race, Mind Control was elevated to first after Far Mo Power was disqualified for interference.  Pletcher said he did not know the identity of the medication, but he characterized it as an overage of medication that is not permissible to be used on raceday. He said the medication “is not something we ever use.” The case is still being adjudicated. “Again, it’s contamination, I’m sure of it,” Pletcher said.  The positive test was first reported by the New York Times.  By any measure, Pletcher is one of the most successful trainers of all time and was elected to racing’s Hall of Fame in 2021 at the age of 53. In 2007, Pletcher served a 45-day suspension for a positive test for mepivacaine, a pain killer, and in 2010 served a 10-day suspension for a procaine positive after his horse Wait a While finished third in the 2008 Breeders’ Cup Filly and Mare Turf. The Forte case has once again exposed an enormous vulnerability for racing at a time when the sport is drawing unwelcome coverage from the mainstream media in the wake of a spate of horse deaths at Churchill Downs and a reputation that has become tarnished over the past several years by a string of court cases revolving around the use of both legal and illegal drugs. If Forte had started in the Derby, the colt’s positive in the Hopeful would have been reported within days of his running in the race. That would have surely resurrected strident criticisms about drug use in racing at the highest levels following the controversy surrounding the 2021 Derby, when the winner, Medina Spirit, trained by Hall of Fame member Bob Baffert, tested positive for a regulated medication. On Wednesday, gaming commission officials cast blame on Pletcher and his legal team for the delay in hearing the case, saying that Pletcher’s attorneys had “sought repeated postponement of the stewards hearing” since the positive was reported last September. In addition, the officials said that finding a “capable” lab to conduct testing on a split sample had also delayed the adjudication. But Murphy, Pletcher’s lawyer, sharply disputed that account, saying that the gaming commission had not provided Pletcher with a list of laboratories that could test the split sample until early in 2023. She also said that the first hearing in the case was scheduled for March, but then she asked for “one or two adjournments” of hearing dates. “The delay is wholly on the gaming commission because they weren’t prepared to proceed with the case in a professional and orderly manner,” Murphy said. “[The perception is] somehow, Todd is gaming the system and is able to do something that others can’t. No one can proceed with anything that others can’t.” Murphy added that “if there was any delay by Todd Pletcher it was maybe two, three, or four weeks.” The Forte incident arose just weeks prior to the expected national launch of HISA’s Anti-Doping and Medication Control program, which is designed to create a national framework for testing of prohibited and regulated medications and the adjudication and enforcement of penalties for violations under the program’s rules. Under that system, the positive by Forte in the Hopeful would have likely been reported to the public within weeks of the finding, and the adjudication process likely would have been over within a month of the race. HISA had hoped to launch the ADMC program last July 1, but logistical delays and litigation by horsemen’s groups and other critics of HISA delayed the launch until earlier this year. Just days after the March 27 launch, a judge delayed the implementation by 30 days, citing a violation of a requirement under the Administrative Procedures Act requiring a 30-day grace period. Shortly thereafter, the Federal Trade Commission, which oversees HISA, extended the delay to May 22, until two days after the running of the second leg of the Triple Crown, the Preakness Stakes. The FTC stated that the reason for the delay was to “avoid chaos and confusion” during the first two legs of the Triple Crown. Although HISA will have jurisdiction over most positive tests that occur on May 22 and beyond, any pending cases, including Forte, will continue to be adjudicated by the regulatory authorities in the state where the case arose. Murphy said that Pletcher “will appeal and we will go all the way and I think we will prevail.” --additional reporting by David Grening :: Want to learn more about handicapping and wagering? Check out DRF's Handicapping 101 and Wagering 101 pages.